Lung Cancer Tumor Board: Dialogues with the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: What Do Current Data for IO- and ALK-Targeted Strategies Tell Us?

Final Slides

Tumor Board #1: Treatment of a Patient With Resected, Stage IB-III NSCLC With an ALK Translocation

Tumor Board #2: Treatment of a Patient With Resectable, Stage IB-III NSCLC and No Actionable Oncogenic Drivers and PD-L1 ≥ 50%